Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.
Avet-Loiseau
Hervé
H
Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France. havetloiseau@chu-nantes.fr
Malard
Florent
F
Campion
Loic
L
Magrangeas
Florence
F
Sebban
Catherine
C
Lioure
Bruno
B
Decaux
Olivier
O
Lamy
Thierry
T
Legros
Laurence
L
Fuzibet
Jean-Gabriel
JG
Michallet
Mauricette
M
Corront
Bernadette
B
Lenain
Pascal
P
Hulin
Cyrille
C
Mathiot
Claire
C
Attal
Michel
M
Facon
Thierry
T
Harousseau
Jean-Luc
JL
Minvielle
Stephane
S
Moreau
Philippe
P
D000368:Aged; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic